AN2 Therapeutics grants inducement equity awards to two new hires

MENLO PARK, Calif., Oct. 23, 2026. AN2 Therapeutics, Inc. (Nasdaq: ANTX) granted inducement equity awards to two newly hired employees on October 19, 2026. The compensation package consists of stock options and restricted stock units.

The awards include options to purchase 10,565 shares of common stock and 5,283 restricted stock units. The option exercise price is set at $3.37 per share, matching the closing price of AN2 Therapeutics common stock on The Nasdaq Global Market on October 19, 2026.

Vesting terms for the non-qualified stock options specify that one quarter of the award vests on the one-year anniversary of the Vesting Commencement Date. Following that initial vesting event, 1/48th of the remaining options vests monthly on the same day of the month as the commencement date. The restricted stock units vest annually over a four-year period and require continuous service with the company to remain eligible.

AN2 Therapeutics' Compensation Committee approved these grants under Nasdaq Listing Rule 5635(c)(4). The committee determined the awards served as a material inducement for the new hires' employment. The grants were issued pursuant to the company's 2026 Employment Inducement Award Plan.

AN2 Therapeutics is a clinical stage biopharmaceutical company developing small molecule therapeutics using its boron chemistry platform. The company's pipeline covers hematologic diseases, infectious diseases, and oncology. Three Phase 2 studies are expected to be active in 2026, alongside two preclinical candidates and advanced research programs targeting oncology, bone disorders, and infectious diseases.

Lucy O. Day serves as Chief Financial Officer. Anne Bowdidge handles investor and media inquiries.